Replicant Competent Virus

In certain situations, the FDA requires testing for replication competent viruses to document the safety of gene therapy products ( PDF). The NGVB offers biologic based assays for virus testing with a focus on testing for retroviral and lentiviral vectors. Assays are performed under Good Manufacturing Practice to meet FDA requirements. Eligible investigators receive testing at a subsidized cost. If you are interested in this service:

Request Testing Services

If you have any questions feel free to contact the NGVB Manager:

NGVB Manager
Please enable JavaScript in your browser to see the e-mail address.